NCT02453672View on ClinicalTrials.gov

Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Healthy
Interventions
BIOLOGICAL

SB8

SB8, proposed bevacizumab biosimilar

BIOLOGICAL

EU sourced Avastin®

EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)

BIOLOGICAL

US Sourced Avastin®

US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)

Trial Locations (1)

Unknown

Samsung Investigational Site, Antwerp

All Listed Sponsors
lead

Samsung Bioepis Co., Ltd.

INDUSTRY

NCT02453672 - Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter